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Abstract. The downstream of tyrosine kinase 7 (DOK7) is 
an adaptor protein mediating signalling transduction between 
receptors and intracellular downstream molecules. Reduced 
expression of DOK7 has been observed in breast cancer. The 
present study aimed to investigate the role played by DOK7 
in lung cancer. The expression of DOK7 at both mRNA and 
protein levels was evaluated in human lung cancer. A reduced 
expression of DOK7 transcripts was seen in lung cancers 
compared with normal lung tissues. Kaplan-Meier analyses 
showed that the reduced expression of DOK7 was associated 
with poorer overall survival and progression-free survival 
of patients with lung cancer. A further western blot analysis 
revealed a predominant expression of DOK7 isoform 1 
(DOK7V1) in normal lung tissues, which was reduced in lung 
cancer. Forced overexpression of DOK7V1 in lung cancer cell 
lines, A549 and H3122 resulted in a decrease of in vitro cell 
proliferation and migration, while adhesion to extracellular 
matrix was enhanced following the expression. In conclusion, 
DOK7 was reduced in lung cancer and reduced DOK7 expres-
sion was associated with poorer survival. DOK7 isoform 1 
plays an inhibitory role on the proliferation and migration of 
lung cancer cells in which Akt pathway may be involved.
Introduction
Lung cancer is the leading cause of cancer death worldwide, 
accounting for 19% of total cancer deaths. The ratio of 
mortality to incidence is 0.87, reflecting the highly fatal nature 
of the disease, despite advances in surgery, chemotherapy and 
radiotherapy (1,2). Lung cancer is categorised into two major 
groups: small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC). NSCLC comprises the majority of lung 
cancers, and is more often diagnosed at an advanced stage 
with poor survival (3). More intensive and effective studies 
are required, to identify new diagnostic, prognostic and thera-
peutic markers, such that improvements can be made in early 
diagnosis and targeted treatments.
From primary tumour to metastasis, cancer cells rely on 
diverse signalling pathways to promote their proliferation, 
survival, invasion and subsequent dissemination through 
lymphatic and blood vessels. Receptor tyrosine kinases (RTKs) 
contain an extracellular domain for ligand binding, a trans-
membrane helix and a cytoplasmic tyrosine kinase domain, 
and an intracellular juxtamembrane regulatory region (4). 
RTKs play a pivotal role in regulation of cellular processes 
including cell survival, cell proliferation, cell differentiation, 
cell migration and cell cycle control (5,6). Dysregulation of 
RTKs, including autocrine activation, chromosomal transloca-
tions, overexpression of RTKs or gain-of-function mutations, 
occurs in cancer (4).
The downstream of kinase (DOK) protein family, 
comprising seven members, mediates intracellular signal 
transduction downstream of RTKs (7-9). DOK proteins share 
a structural topology characterised by an NH2-terminal 
pleckstrin homology (PH) domain, a central phosphotyrosine 
binding (PTB) domain, followed by SH2 target motifs in the 
carboxyl-terminal (7,10). The DOK proteins are divided into 
three subgroups; DOK 1-3 are primarily expressed in haema-
topoietic tissues (11), DOK 4-6 are predominantly expressed 
within the nervous system (12,13), and DOK7 is mainly 
expressed in skeletal muscle and the heart, and plays a distinct 
role in comparison with the other members (14).
Deregulation of DOK proteins have been observed in 
various malignancies. DOK1, DOK2, and DOK3 have been 
shown to cooperatively suppress aggressive histiocytic 
sarcoma in a mouse model (11). DOK2 has been suggested as 
a predictive factor for poor prognosis of gastric cancer (15,16). 
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In lung cancer, loss of DOK1, DOK2 and DOK3 resulted in 
aberrant proliferation of alveolar type II cells and bronchoal-
veolar stem cells, with subsequent development of lung cancer 
in a mouse model (7). Reduced expression of DOK2 was also 
seen in human lung cancers, and a forced overexpression of 
DOK2 inhibited the proliferation of lung cancer cells (7).
DOK7 is a cytoplasmic adaptor protein that is necessary for 
muscle specific kinase (MuSK) activation and Acetylcholine 
receptor (AChR) clustering, which are indispensible for neuro-
muscular synapse function (17,18). DOK7 interacts with the 
juxtamembrane region of MuSK via its PTB domain, although 
both PH and PTB domains are required for MuSK activa-
tion (18-20). DOK7 is not only a substrate of MuSK, but can 
also activate MuSK kinase activity (21). Agrin requires DOK7 
to activate MuSK and DOK7 is also necessary for the correct 
localisation of MuSK in muscle (22). Overexpression of DOK7 
was associated with increased activation of MuSK and neuro-
muscular junction formation (22). On the other hand, DOK7 
expression enhanced MuSK activation and restored neuro-
muscular junction formation in agrin-deficient mice (23,24). 
In addition to its profound function at neuromuscular junction, 
a recent study has revealed a hypermethylation of DOK7 
promoter in breast cancer (25). However, the expression and 
biological function of DOK7 in other malignancies, particu-
larly lung cancer, remains largely unknown.
In the present study, we aimed to evaluate DOK7 
expression in lung cancer and the involvement in disease 
progression. Our current study revealed predominant expres-
sion of DOK7 protein isoform 1 (DOK7V1) in normal lung 
tissues, which was reduced in lung cancers. We further inves-
tigated its regulatory role of cellular functions in lung cancer 
cell lines using an overexpression plasmid vector carrying a 
DOK7V1 coding sequence.
Materials and methods
Cell culture. Lung cancer cell lines, A549 and H3122 were 
purchased from the American Type Culture Collection (ATCC, 
Manassas, VA, USA). Cells were routinely cultured in Dulbecco's 
modified Eagle's medium (DMEM) with L-glutamine (Thermo 
Fisher Scientific, Hudson, NH, USA) supplemented with 10% 
fetal bovine serum (ExCellBio, Shanghai, China), in an incu-
bator at 37˚C, 5% CO2 and 95% humidity.
Construction of DOK7 expression vectors and transfec-
tion: the DOK7-Flag and pEnter (vector) plasmids were 
purchased from Vigene Biosciences (Rockville, MD, USA). 
Purified DOK7V1 transgenes and control plasmid vectors 
were transfected into A549 and H3122 cells, respectively, 
using Neofect™ DNA transfection reagent (Neofectbiotech 
Co., Ltd., Beijing, China).
Western blot analysis. Protein concentrations were determined 
with the BCA Protein Assay kit and a spectrophotometer 
(both by Thermo Fisher Scientific). Equal amounts of protein 
sample were separated using 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and blotted 
onto a nitrocellulose membrane. The membranes were blocked 
with 5% skimmed milk in TBS buffer for 1 h. Proteins were 
then probed with anti-FLAG monoclonal antibody (Sigma, 
St. Louis, MO, USA), anti-DOK7 antibody (Abcam, Cambridge, 
MA, USA), monoclonal mouse anti-human GAPDH antibody 
(Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-Akt 
antibody (Sigma) and anti-phosphorylated-Akt (Ser473, Cell 
Signaling Technology, Danvers, MA, USA) and corresponding 
peroxidase-conjugated secondary antibody. Protein bands 
were visualised and analysed using Vilber Fusion Fx5 (Vilber, 
Marne La Vallée, France).
In vitro cell function assays. Cells were detached from the 
culture dish and cell density (per millilitre) was counted. Cells 
were then seeded onto a 96-well plate at a density of 3000 cells 
in 200 µl of culture medium. Five plates were set up to obtain 
a cell density reading, following incubation up to 4 days. After 
the incubation, culture medium was removed and replaced 
with 100 µl of 10% CCK-8 (Cell Counting Kit-8, Dojindo, 
Japan). Absorbance at 450 nm was then determined after an 
incubation at 37˚C, 5% CO2 for 1 h using a spectrophotometer 
(Thermo Fisher Scientific).
In vitro tumour cell Matrigel adhesion assay. Matrigel (5 µg) 
was added to 100 µl of serum-free medium to coat the culture 
surface of each well of a 96-well plate and dried in an oven to 
form an artificial basement membrane. This membrane was 
then rehydrated in 100 µl of sterile distilled water for 40 min 
before seeding 20,000 cells/200 µl culture medium into each 
well. After an incubation of 40 min, the medium was removed 
and non-adherent cells were washed off with 150 µl of PBS 
buffer. Adherent cells were then fixed in 4% formaldehyde 
(v/v) in PBS for 30 min before being stained in 0.5% crystal 
violet solution (w/v) in distilled water. Crystal violet staining 
was dissolved with 10% acetic acid and the absorbance at 
570 nm was then determined using the spectrophotometer.
In vitro tumour cell migration assay. Cells (1x106/well) were 
seeded to a 6-well plate and cultured in the incubator overnight, 
then scratched with a 200 µl pipette tip to create a wound and 
washed twice with PBS to remove floating cells. The cells were 
photographed every 6 h using an inverted microscope over a 
period up to 24 h. The size of the wounds were subsequently 
measured with ImageJ software.
Results
Expression of DOK7 in lung cancer. We initially evaluated the 
expression of DOK7 in lung cancer by analysing its levels in a 
cohort of lung cancer tissue deposited at The Cancer Genome 
Atlas (TCGA) adenocarcinoma database. Reduced transcript 
levels of DOK7 were seen in the lung cancer compared with 
normal lung tissues (Fig. 1A). We also analysed DOK7 expres-
sion levels in another cohort of lung cancer which had paired 
adjacent normal lung tissues (GSE19804, 240633_at) (26). 
The reduced expression of DOK7 was also seen in these lung 
cancer samples in comparison with the paired adjacent normal 
lung tissues, p<0.001 (Fig. 1B).
Reduced expression of DOK7 was associated with the 
survival of patients with lung cancer. To further clarify the 
role played by this molecule in lung cancer, we analysed the 
association between DOK7 expression (Affy ID 240633_at) 
and survival of patients with lung cancer using an online 
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Kaplan-Meier survival analysis tool (KMplot, http://kmplot.
com/analysis/) (27). The Kaplan-Meier analyses showed that 
the reduced expression of DOK7 was significantly associated 
with poorer overall survival (OS), p<0.001 (Fig. 2A), in a cohort 
of 1145 cases of lung cancer. The reduced DOK7 expression 
was also associated with poor progression-free survival (PFS) 
of a cohort of 596 patients with lung cancer, p=0.019 (Fig. 2B).
Expression of DOK7 protein isoforms in human lung cancer 
tissues. The expression of DOK7 protein isoforms was exam-
ined in a cohort of lung cancer tissues using western blot 
analysis. DOK7 isoform 1 (DOK7V1) was predominantly 
expressed in normal lung tissues in comparison to the expres-
sion of its isoform 2 (DOK7V2) (Fig. 3). DOKV1 exhibited 
low expression in lung cancer tissues compared with the paired 
adjacent normal lung tissues (p<0.01, n=12). DOK7V2 protein 
was either weakly expressed or absent from both lung cancer 
tissues and adjacent normal lung tissues (Fig. 3).
Overexpression of DOK7V1 exhibited an inhibitory effect 
on proliferation of lung cancer cell lines. To further study 
the role of DOK7 in lung cancer, we constructed an over-
expression plasmid vector which carried the coding sequence 
of DOK7V1. Overexpression of DOK7V1 was performed in 
A549 and H3122 lung cancer cell lines. Following transfec-
tion and selection, transfected cell lines were verified for the 
expression of DOK7V1 using western blotting (Fig. 4A). The 
overexpression of DOK7V1 resulted in a reduction of in vitro 
cell proliferation of A549 cells compared with the control 
cells which were transfected with the empty plasmid vector 
(Fig. 4B). In comparison with the A549 cells, H3122 exhib-
ited less response to the inhibitory effect on proliferation by 
DOK7V1 overexpression (Fig. 4C).
Influence of DOK7V1 on adhesion and migration of lung 
cancer cells. The overexpression of DOK7V1 resulted in an 
increase in cell adhesion to an artificial matrix gel in both 
A549 and H3122 lung cancer cell lines (Fig. 5). In contrast 
to the promotion of cellular adhesion, a reduction was seen in 
the migration of both A549 and H3122 cell lines following the 
overexpression of DOK7V1 in comparison with the respective 
control cells (Fig. 6).
Figure 1. Expression of DOK7 transcripts in human lung cancer. (A) Transcript levels of DOK7 were analysed in a cohort of lung cancers (515 cases) compared 
with normal lung tissues (59 cases) which were obtained from a collection of gene expression array data at TCGA (http://www.cbioportal.org/data_sets.jsp). 
(B) DOK7 expression in lung cancer compared with paired adjacent normal lung tissues (GSE19804) was analysed using paired t-test. ***p<0.001.
Figure 2. DOK7 expression and survival of patients with lung cancer. Association between DOK7 expression and overall survival (OS, A) and progression-free 
survival (PFS, B) was analysed using an online Kaplan-Meier survival analysis (KMplot, http://kmplot.com/analysis/). An auto-selected cut-off value of 115 
was employed in the analysis.
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Phosphorylation of Akt was altered in the DOK7V1 over-
expression lung cancer cell lines. Following the functional 
assays, we performed some experiments to examine involve-
ment of Akt and ERK pathways which have shown associated 
with functions of certain DOK proteins (7). A decrease of 
Akt phosphorylation was seen in both A549 and H3122 cell 
lines which overexpressed the DOK7 variant 1 while the total 
Akt protein levels remained similar in comparison with their 
corresponding controls (Fig. 7).
Discussion
This is the first study regarding the downstream of tyrosine 
kinase 7 (DOK7) in lung cancer, in which we determined 
protein isoform -1 and -2 expression levels in human lung 
cancer tissues, compared with paired adjacent normal lung 
tissues. In the present study, a reduced transcript level of 
DOK7 was seen in lung cancer in comparison to normal 
lung tissues or paired adjacent normal lung tissues. Western 
blot analyses further revealed that one of the DOK7 protein 
isoforms, isoform 1 (DOKV1) was predominantly expressed 
in the normal lung tissues, and was reduced in lung cancers.
Recent studies of other DOK proteins in lung cancers have 
demonstrated that DOK1, DOK2 and DOK3 are reduced or 
absent in lung cancer (7,28). In mouse models, loss of DOK1, 
DOK2 and DOK3 resulted in an increased proliferation of 
alveolar type II cells and bronchoalveolar stem cells leading to 
a development of lung cancer particularly in a triple knockout 
mouse model (7). A reduced expression of DOK2 was also 
observed in human lung adenocarcinomas, whilst DOK2 
overexpression resulted in an inhibition of proliferation of 
lung cancer cells (7). Chromosome 8p21.3 where DOK2 gene 
is located, is one of the common regions deleted in human 
lung cancer (28). The loss of one copy of the DOK2 gene 
was seen in 37% of human lung adenocarcinoma and 33% of 
Figure 3. DOK7 protein isoform-1 (DOK7V1) and -2 (DOK7V2) were 
determined in 12 lung cancer tumours together with paired adjacent normal 
lung tissues using western blotting. (A) Shown are representatives from 
the 12-paired lung cancer samples of western blotting. A semi-quantitative 
analysis was performed using ImageJ. Shown are values of band integrated 
density normalised against the corresponding loading control (GAPDH), 
DOK7V1 (B), and DOK7v2 (C), respectively. **p<0.01.
Figure 4. Overexpression of DOK7V1 in lung cancer cell lines and the effect 
on in vitro proliferation. (A) The forced overexpression of DOK7V1 was con-
firmed using western blotting. The influence of DOK7V1 was determined 
using an in vitro colorimetric growth assay for A549 (B) and H3122 (C) lung 
cancer cell lines in comparison with their corresponding control cell lines 
which were transfected with the empty plasmid vector. Six repeats were 
performed for each cell line in each experiments. Three independent experi-
ments were carried out. Shown are representative data. Error bars represent 
standard deviations. *p<0.05; **p<0.01.
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human non-small cell lung cancers (7). Reduced expression 
of DOK2 was seen in both primary lung adenocarcinomas 
and lymph node metastases (7). In contrast to the observation 
in mouse models, no differential expression of DOK1 and 
DOK3 was seen in human lung cancer in comparison with 
normal lung tissues, although a reduced DOK3 was noted in 
lymph node metastases compared with its expression in the 
primary tumours (7). 
A recent study of DOK7 in breast cancer has demonstrated 
that CpG islands of DOK7 promoter are hypermethylated 
leading to a downregulation its expression (25). These studies 
indicate that an inhibitory role may be played by DOK 
Figure 5. DOK7V1 overexpression and adhesiveness of lung cancer cell lines. The adhesion to extracellular matrix was determined using an adhesion assay for 
A549 (A) and H3122 (B) cell lines, respectively. Six repeats were included for each cell lines in every adhesion assay and three independent experiments were 
performed. Shown are representative data. **p<0.01.
Figure 6. Migration of DOK7V1 overexpression cell lines were determined using a wound assay for A549 (A and B) and H3122 (C and D). Three independent 
experiments were performed. Error bars are standard deviations. *p<0.05 and **p<0.01.
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proteins in cancer. Downregulation or loss of DOK proteins 
may occur in cancer cells due to gene deletion or hypermeth-
ylation. Additionally, mutations in DOK7 are a common cause 
of congenital myasthenic syndrome (29). However, whether 
the reduced expression or loss of DOK7 in lung cancer results 
from these events is yet to be investigated. The role of DOK7 
mutation in cancer also requires investigation.
Kaplan-Meier survival analyses of DOK7 transcripts in 
lung cancer show that the reduced transcript levels of DOK7 
were associated with both poorer OS and PFS. It suggests that 
DOK7 plays an inhibitory role during disease progression 
and relapse of lung cancer. To further explore this hypoth-
esis, we constructed a plasmid vector carrying a DOK7V1 
coding sequence. Overexpression of this isoform resulted in a 
decreased proliferation of both A549 and H3122 lung cancer 
cell lines. In keeping with the inhibitory role of DOK proteins 
in lung cancer, forced expression of DOK2 in a lung cancer 
cell line has been seen to reduce growth rate and both Akt and 
Erk phosphorylation (7).
It has been suggested that certain DOK proteins play an 
inhibitory role in signal transduction of some RTKs, therefore 
the loss of these DOK proteins leads to a promotion of the 
RTK-mediated proliferation. Further study will elucidate 
the role played by DOK7 in RTK signalling and the disease 
progression of lung cancer.
In addition to its effect on cell proliferation, a similar 
inhibitory effect was also observed in migration of both A549 
and H3122 cell lines following the overexpression of DOK7V1. 
Moreover, a contrasting effect was seen in adhesion of these 
cell lines to an artificial basement membrane, with DOK7V1 
enhancing the adhesiveness of these lung cancer cell lines. Our 
further investigations showed a reduced activation of Akt in the 
lung cancer cell lines following the overexpression of DOK7 
variant 1. However, how DOK7 protein coordinates signalling 
through Akt pathway and what implication DOK7-regulated 
Akt pathway has in lung cancer are yet to be investigated in 
future study.
In conclusion, DOK7 transcripts were reduced in lung 
cancer and the reduced DOK7 transcript levels were associ-
ated with poorer OS and PFS. DOK7 protein isoform 1 was 
more abundantly expressed in normal lung tissues and was 
reduced in lung cancers. Overexpression of the DOK7 isoform 
1 inhibited proliferation and migration of lung cancer cells in 
which a reduced activation of Akt was observed, but enhanced 
the adhesion of lung cancer cells to extracellular matrix. 
Further investigations are needed to shed light on the inter-
action between DOK7 and RTKs, including the RTK-mediated 
signalling that enhanced as a result of DOK7 downregulation, 
thus leading to disease progression and relapse.
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